Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kobotide is a synthetic peptide derived from the venom of the Chinese red-headed centipede (Scolopendra subspinipes mutilans). It is classified as an antimicrobial peptide and has demonstrated potent antibacterial activity, particularly against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Kobotide exerts its effects by disrupting bacterial cell membranes, leading to cell death. In addition to its antimicrobial properties, preliminary research suggests it may have anti-inflammatory and immunomodulatory effects. Kobotide is primarily studied in preclinical settings for potential use as a novel antibiotic or anti-infective agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kobotide.